<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38125892</article-id><article-id pub-id-type="pmc">PMC10731352</article-id><article-id pub-id-type="publisher-id">1341004</article-id><article-id pub-id-type="doi">10.3389/fphar.2023.1341004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Editorial</subject></subj-group></subj-group></article-categories><title-group><article-title>Editorial: Molecular mechanism and pharmacology of metabolism and cardiac remodeling</article-title><alt-title alt-title-type="left-running-head">Chen et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2023.1341004" ext-link-type="uri">10.3389/fphar.2023.1341004</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Mengya</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2591759/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Saiyang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1049248/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Deng</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/462222/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Cardiology</institution>, <institution>Renmin Hospital of Wuhan University</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Hubei Key Laboratory of Metabolic and Chronic Diseases</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited and reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/11865/overview" ext-link-type="uri">Eliot Ohlstein</ext-link>, Drexel University, United States</p></fn><corresp id="c001">*Correspondence: Wei Deng, <email>vivideng1982@whu.edu.cn</email>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><elocation-id>1341004</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Chen, Xie and Deng.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Chen, Xie and Deng</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="RA1" xlink:href="https://www.frontiersin.org/researchtopic/44190" ext-link-type="uri" journal-id="Front. Pharmacol.">Editorial on the Research Topic <article-title>Molecular mechanism and pharmacology of metabolism and cardiac remodeling</article-title>
</related-article><kwd-group><kwd>metabolism</kwd><kwd>cardiac remodeling</kwd><kwd>heart failure</kwd><kwd>molecular mechanism</kwd><kwd>immunometabolism</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work received support from funding sources: the National Key R&#x00026;D Program of China (2018YFC1311300); The Regional Innovation and Development Joint Fundof National Natural Science Foundation of China (No. U22A20269); the National Natural Science Foundation of China (No.82170245, 82370284); the Fundamental Research Funds for the Central Universities (2042018kf1032).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cardiovascular and Smooth Muscle Pharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The progress of Heart failure (HF) is associated with insufficient energy, substrate utilization disorders, and oxidative stress. In cardiac injuries, metabolic remodeling often precedes most changes (<xref rid="B1" ref-type="bibr">Lopaschuk et al., 2021</xref>). The Research Topic encompasses studies related to cardiac immunometabolism, mitochondrial metabolism, molecular biomarkers, special case report and drug development and treatment for heart failure.</p><p>Deviant mitophagy has been proved to induce energy metabolism dysfunction in the course of cardiac pathological events (<xref rid="B2" ref-type="bibr">Ranjbarvaziri et al., 2021</xref>). <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1118017/full" ext-link-type="uri">Zhou et al.</ext-link> discovered that mesaconine, a major cardiotonic component of Fuzi, significantly rescued cardiac dysfunction and impaired mitophagy in cardiomyocytes of mice administered doxorubicin. Furthermore, the role of mesaconine is mediated by the activation of PINK1-induced mitophagy. These results hold substantial significance for the development of clinical trials with mesaconine. Through pharmacology experiments in rhesus monkeys and rats, <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.1080645/full" ext-link-type="uri">Zhang et al.</ext-link> demonstrated beneficial effects of QiShenYiQi Dripping Pills (QSYQ) on HF, which may be associated with pathways involved in myocardial energy metabolism. These findings establish a groundwork for the potential clinical application of QSYQ. <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1111007/full" ext-link-type="uri">Zhong et al.</ext-link> illustrated that traditional Chinese medicine QWQXI combined with western medicine therapy can enhance cardiac function in patients with chronic heart failure. QWQXI modulated inflammation mediated by glycerophospholipid and linoleic acid metabolism, thereby improving cardiac function in HF rats. This study provides a novel molecular foundation for investigating the intervention mechanisms of QWQXI. These findings offer new options for treating HF.</p><p>Immunometabolism plays an important role in the progression of cardiovascular remodeling (<xref rid="B4" ref-type="bibr">Williams et al., 2019</xref>). <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.1079185/full" ext-link-type="uri">Meng et al.</ext-link> reviewed the latest researches on the immunometabolism and therapeutic strategies for atherosclerosis. The existence of immune cells and immune factors was related to atherosclerosis and atherosclerosis might be attenuated through the defensive immune response triggered by specific autoantigens or exogenous antigens. It reveals the potential of immunotherapy as a novel therapeutic strategy for atherosclerosis.</p><p>
<ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1145413/full" ext-link-type="uri">Zheng et al.</ext-link> demonstrated the possible mechanisms by which endogenous n-3 polyunsaturated fatty acids (n-3 PUFA) exerted protective effects against cardiac ischaemia-reperfusion (IR) injury. It was the first report that identified n-3 PUFA protected the heart by modulating the APLNR-dependent PI3K-AKT-mTOR signaling axis in the IR heart. These findings were further evidence that n-3 PUFA can protect mitochondrial structure and function. Previous studies have found a correlation between abnormal lipid metabolism and the progression of atrial fibrillation (AF) (<xref rid="B3" ref-type="bibr">Suffee et al., 2022</xref>). Utilizing ultra-high-performance lipidomics analysis, <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1148410/full" ext-link-type="uri">Huang et al.</ext-link> determined that phosphatidylethanolamine (PE) was correlated with AF. Further, they identified that PE may exacerbate Ang II-induced atrial fibrosis through inducing mitochondrial damage and ferroptosis in cardiomyocytes. This study suggested that inhibiting PE and ferroptosis may be a promising therapeutic strategy for AF.</p><p>
<ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.1018394/full" ext-link-type="uri">Zou et al.</ext-link> presented a case report of idiopathic hypereosinophilic syndrome (IHES) complicated with intracardiac thrombus, which is a rare cardiac complication of HIS. Based on this case, novel oral anticoagulant (NOAC) therapy may be an effective option. This case contributed to a better comprehension of the pathology and cardiac complications of IHES.</p><p>In conclusion, the &#x0201c;Molecular Mechanism and Pharmacology of Metabolism and Cardiac Remodeling&#x0201d; Research Topic focuses on recent insights into the molecular mechanism and pharmacology in cardiac metabolic remodeling and novel therapeutic targets for cardiac remodeling and heart failure.</p></body><back><sec id="s1"><title>Author contributions</title><p>MC: Writing&#x02013;original draft, Writing&#x02013;review and editing. SX: Writing&#x02013;review and editing. WD: Writing&#x02013;review and editing.</p></sec><sec sec-type="COI-statement" id="s3"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="disclaimer" id="s4"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopaschuk</surname><given-names>G. D.</given-names></name><name><surname>Karwi</surname><given-names>Q. G.</given-names></name><name><surname>Tian</surname><given-names>R.</given-names></name><name><surname>Wende</surname><given-names>A. R.</given-names></name><name><surname>Abel</surname><given-names>E. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Cardiac energy metabolism in heart failure</article-title>. <source>Circ. Res.</source>
<volume>128</volume>, <fpage>1487</fpage>&#x02013;<lpage>1513</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318241</pub-id>
<pub-id pub-id-type="pmid">33983836</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranjbarvaziri</surname><given-names>S.</given-names></name><name><surname>Kooiker</surname><given-names>K. B.</given-names></name><name><surname>Ellenberger</surname><given-names>M.</given-names></name><name><surname>Fajardo</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Vander Roest</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy</article-title>. <source>Circulation</source>
<volume>144</volume>, <fpage>1714</fpage>&#x02013;<lpage>1731</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.053575</pub-id>
<pub-id pub-id-type="pmid">34672721</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suffee</surname><given-names>N.</given-names></name><name><surname>Baptista</surname><given-names>E.</given-names></name><name><surname>Piquereau</surname><given-names>J.</given-names></name><name><surname>Ponnaiah</surname><given-names>M.</given-names></name><name><surname>Doisne</surname><given-names>N.</given-names></name><name><surname>Ichou</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Impacts of a high-fat diet on the metabolic profile and the phenotype of atrial myocardium in mice</article-title>. <source>Cardiovasc Res.</source>
<volume>118</volume>, <fpage>3126</fpage>&#x02013;<lpage>3139</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvab367</pub-id>
<pub-id pub-id-type="pmid">34971360</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>J. W.</given-names></name><name><surname>Huang</surname><given-names>L. H.</given-names></name><name><surname>Randolph</surname><given-names>G. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Cytokine circuits in cardiovascular disease</article-title>. <source>Immunity</source>
<volume>50</volume>, <fpage>941</fpage>&#x02013;<lpage>954</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.007</pub-id>
<pub-id pub-id-type="pmid">30995508</pub-id>
</mixed-citation></ref></ref-list></back></article>
